Ascierto PA, Del Vecchio M, Robert C, Mackiewicz A, Chiarion-Sileni V, Arance A, et al. Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 2017 Mar 27 Abstract available at http://www.ncbi.nlm.nih.gov/pubmed/28359784.
Compare quality appraisals for each clinical question
- Does systemic drug therapy improve progression-free, overall survival in unresectable stage III and stage IV melanoma?
- Immunotherapy for melanoma
- What is the role of adjuvant systemic therapy in patients with resected stage II and stage III melanoma?